Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.

作者: J Michael Tredger , Nigel W Brown , Anil Dhawan

DOI: 10.2165/00003495-200868100-00004

关键词:

摘要: Despite their efficacy, the calcineurin inhibitors (CNIs) ciclosporin and tacrolimus carry a risk of debilitating adverse effects, especially nephrotoxicity, that affect long-term outcome survival children who are given organ transplants. Simple reduction in dosage CNI has little or no benefit on complete withdrawal without threatening graft may only be possible after liver transplantation. Until last decade, option was to increase corticosteroid and/or azathioprine doses, which imposed additional hazards. Considered here emerging generation new agents offering an opportunity for improving survival, minimizing CNI-related events ensuring patient well-being. A holistic, multifaceted strategy need considered — initial selection optimized use monitoring immunosuppressant regimens, early recognition indicators dysfunction, and, where applicable, introduction CNI-sparing regimens facilitating withdrawal. The evidence reviewed supports these approaches but remains far from definitive paediatric solid Because de novo immunosuppression uses more than 93% patients, effects focused sparing recurring theme sirolimus mycophenolate mofetil have been used this purpose is importance limit damage provide benefit: example, renal function critically reflects at 1 year post-transplant. While mycophenolic acid shows advantages over preserving because latter associated with proteinuria, appears potent also impairs wound healing. CNI-free depleting non-depleting antibodies plus needs much wider investigation achieve acceptable rejection rates conserve function. alternative immunosuppressants, particularly dyslipidaemia sirolimus, minimized avoid replacing one set (from CNIs) another. we can conjecture judicious combinations second novel immunosuppressants currently development will solutions, rationale low-dose therapy multiple acting by complementary mechanisms seems hold promise efficacy minimal toxicity until vision tolerance achieves reality.

参考文章(306)
Faisal Khan, Swati Agrawal, Suraksha Agrawal, Genetic Predisposition and Renal Allograft Failure Molecular Diagnosis & Therapy. ,vol. 10, pp. 205- 219 ,(2006) , 10.1007/BF03256459
Helio Tedesco Silva, Paula Pinheiro Machado, Claudia Rosso Felipe, Jose Osmar Medina Pestana, Immunotherapy for De Novo renal transplantation: what's in the pipeline? Drugs. ,vol. 66, pp. 1665- 1684 ,(2006) , 10.2165/00003495-200666130-00002
Sirolimus in pediatric solid organ transplantation. Pediatric Transplantation. ,vol. 9, pp. 427- 429 ,(2005) , 10.1111/J.1399-3046.2005.00385.X
Elias David-Neto, Lilian Monteiro Pereira Araujo, Nairo Massakazu Sumita, Maria Elizabeth Mendes, Maria Cristina Ribeiro Castro, Cristiane Feres Alves, Erica Kakehashi, Paschoalina Romano, Elisa Midori Yagyu, Margaret Queiroga, William Carlos Nahas, Luiz Estevam Ianhez, Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation Pediatric Nephrology. ,vol. 18, pp. 266- 272 ,(2003) , 10.1007/S00467-002-1057-1
C. P. Larsen, S. J. Knechtle, A. Adams, T. Pearson, A. D. Kirk, A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression American Journal of Transplantation. ,vol. 6, pp. 876- 883 ,(2006) , 10.1111/J.1600-6143.2006.01259.X
Angela C Webster, Rod RS Taylor, Jeremy R Chapman, Jonathan C Craig, None, Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews. ,vol. 2005, ,(2005) , 10.1002/14651858.CD003961.PUB2
Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi, From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. American Journal of Transplantation. ,vol. 4, pp. 299- 310 ,(2004) , 10.1111/J.1600-6143.2004.00312.X
R. Grenda, A. Watson, K. Vondrak, N. J. A. Webb, J. Beattie, M. Fitzpatrick, M. A. Saleem, R. Trompeter, D. V. Milford, N. E. Moghal, D. Hughes, F. Perner, S. Friman, R. Van Damme-Lombaerts, F. Janssen, A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. American Journal of Transplantation. ,vol. 6, pp. 1666- 1672 ,(2006) , 10.1111/J.1600-6143.2006.01367.X
V. C. McAlister, E. Haddad, E. Renouf, R. A. Malthaner, M. S. Kjaer, L. L. Gluud, Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis American Journal of Transplantation. ,vol. 6, pp. 1578- 1585 ,(2006) , 10.1111/J.1600-6143.2006.01360.X
James J. Zimmerman, Geraldine M. Ferron, Vernon Parker, Heng‐Keang Lim, The Effect of a High-Fat Meal on the Oral Bioavailability of the Immunosuppressant Sirolimus (Rapamycin) The Journal of Clinical Pharmacology. ,vol. 39, pp. 1155- 1161 ,(1999) , 10.1177/009127009903901107